

F. No. BIO/CT/18/000052
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

FDA Bhawan, Kotla Road
New Delhi-110002

From,

The Drugs Controller General, India
Directorate General of Health Services,

To,

M/s Takeda Pharmaceutical India Pvt. Ltd,
The Capital, Unit No. 1504,
Plot No. C-70, G-block,
Bandra-Kurla Complex,
Bandra East Mumbai - 400 051,
Maharashtra.

Subject:- Application for grant of permission to conduct Phase IV study entitled "A Multicenter, Single-arm, open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Vedolizumab in Indian Patients With Ulcerative Colitis and Crohn's Disease" vide Protocol No. Vedolizumab-4020, Version 01, dated 19.10.2019 – regarding

Ref:- (1). Your application Ref. No. BIO/Form44/FF/2018/9148, dated 26-Jul-2018.

(2). Minutes of 24th SEC (Gastroenterology & Hepatology) meeting held on 10.12.2019.

Sir,

This Directorate has no objection to your conducting subject mentioned study under the provisions of New Drugs and Clinical Trial Rules, 2019 under the supervision of the investigators mentioned below as per Protocol No. Vedolizumab-4020, Version 01, dated 19.10.2019 forwarded to this Directorate subject to condition that during the follow-up period of the subject clinical trial also the sponsor shall provide the cost of treatment and the subject study shall be completed within 3 years.

S. No	Name of Investigator	Clinical Trial Site address	Name and Address of the Ethics Committee
1	Dr. Ajit Sood	Dayanand Medical College and Hospital, Civil Lines Tagore Nagar Ludhiana-141001, Punjab.	Drug Trials Ethics Committee, Basement, Hero, Dayanand Medical college Heart Institute, Opposite Library, Dayanand Medical college and Hospital, Civil Lines, Tagore Nagar Ludhiana - 141 001, Punjab Registration No. ECR/101/Inst/PB/2013/RR-16

2	Dr. B Ramesh Kumar	Osmania General Hospital, Golden Jubilee Block, Afzalgunj, Hyderabad – 500 012, Telangana.	Institutional Ethics Committee, Osmania Medical College, Koti Hyderabad-500 095, Telangana. Registration No. ECR/300/Inst/AP/2013/RR-16
3	Dr. Abraham Koshy	Lakeshore Hospital and Research Centre Limited, NH -47 Bypass, Maradu, Nettoor P.O, Kochi– 682040, Kerala.	Lakeshore Ethics Committee, Lakeshore Hospital and Research Centre Ltd, NH-47 Bypass, Maradu, Nettoor P.O, Kochi– 682040, Kerala. Registration No. ECR/115/Inst/Ker/2013/RR-19
4	Dr. Vishwa Mohan Dayal	Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar - 800014	Institutional Ethics Committee, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna - 800014, Bihar. Registration No. ECR/640/Inst/BR/2014/RR-17
5	Dr. Adi Rakesh Kumar	Glenegales Global Hospitals, 6-1-1070/1 to 4, Lakdikaphool, Hyderabad – 500004.	Institutional Ethics Committee Glenegales Global Hospitals, Glenegales Global Hospitals, 6 -1-1070/1 to 4, Lakdikapool, Hyderabad – 500004. Registration No. ECR/158/Inst/AP/2013/RR - 16

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- i. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- ii. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- iii. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- iv. The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- v. Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- vi. Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- vii. Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- viii. Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- ix. In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- x. Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- xi. In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- xii. In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- xiii. The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- xiv. Where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licensing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

- xv. The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- xvi. The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- xvii. The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority